Table 4 Univariate and multivariate Cox analysis of risk factors for the development of herpes zoster in kidney transplant patients, (n = 450)
Risk Factors | Hazard ratio | 95 % Confidence Interval | p-value |
|---|---|---|---|
Univariate analysis | |||
Age, (years) | |||
< 60 | 1.00 (referent) | ||
≥ 60 | 2.598 | 1.180 - 5.721 | 0.018 |
Gender | |||
Female | 1.00 (referent) | - | - |
Male | 0.671 | 0.323-1.396 | 0.286 |
Pre-transplant VZV disease | |||
No/Unknown | 1.00 (referent) | - | - |
Yes | 10.777 | 3.262-35.612 | 0.0001 |
Induction agent | |||
None | 1.00 (referent) | - | - |
Anti-thymocyte globulin (ATG) | 0 | 0- n.ea | 0.977 |
Basiliximab | 0.36 | 0.81-1.612 | 0.182 |
Daclizumab | 0.39 | 0.89-1.709 | 0.211 |
Rejection treatment | |||
No | 1.00 (referent) | - | - |
Yes | 2.08 | 0.624-6.930 | 0.233 |
Multivariate analysis | |||
Age, (years) | |||
< 60 | 1.00 (referent) | ||
≥ 60 | 3.995 | 1.790-8.915 | 0.001 |
Pre-transplant VZV disease | |||
No/Unknown | 1.00 (referent) | - | - |
Yes | 16.022 | 4.624-55.522 | 0.008 |
Rejection treatment | |||
No | 1.00 (referent) | - | - |
Yes | 5.566 | 1.562-19.835 | 0.0001 |